

# Miriam Koopman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7923169/publications.pdf>

Version: 2024-02-01

136  
papers

7,662  
citations

117625

34  
h-index

54911

84  
g-index

136  
all docs

136  
docs citations

136  
times ranked

9800  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 563-572.	27.0	1,243
2	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389.	27.8	764
3	Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. <i>Lancet</i> , The, 2007, 370, 135-142.	13.7	593
4	Mismatch Repair Status and <i>BRAF</i> Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. <i>Clinical Cancer Research</i> , 2014, 20, 5322-5330.	7.0	561
5	From tumour heterogeneity to advances in precision treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 235-246.	27.6	466
6	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> , The, 2016, 17, 1709-1719.	10.7	442
7	Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. <i>Lancet</i> , The, 2015, 385, 1843-1852.	13.7	421
8	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2015, 16, 1639-1650.	10.7	277
9	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology</i> , The, 2018, 19, 1459-1467.	10.7	238
10	Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. <i>Annals of Surgical Oncology</i> , 2011, 18, 3252-3260.	1.5	158
11	Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. <i>Clinical Cancer Research</i> , 2017, 23, 387-398.	7.0	128
12	Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 30.	5.4	111
13	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018, 110, 638-648.	6.3	90
14	Insights into the Dose-Response Relationship of Radioembolization with Resin <sup>90</sup> Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1014-1019.	5.0	88
15	A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. <i>European Journal of Cancer</i> , 2009, 45, 1935-1949.	2.8	87
16	Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). <i>BMC Cancer</i> , 2019, 19, 390.	2.6	83
17	Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. <i>European Journal of Cancer</i> , 2009, 45, 1999-2006.	2.8	82
18	Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 803-813.	7.3	65

#	ARTICLE	IF	CITATIONS
19	A cost analysis of upfront DPYD genotypeâ€“guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019, 107, 60-67.	2.8	65
20	Genomic landscape of metastatic colorectal cancer. <i>Nature Communications</i> , 2014, 5, 5457.	12.8	61
21	Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. <i>British Journal of Cancer</i> , 2018, 119, 1244-1251.	6.4	57
22	Management of cytotoxic chemotherapy-induced hand-foot syndrome. <i>Oncology Reviews</i> , 2020, 14, 442.	1.8	56
23	Perceived Care and Well-being of Patients With Cancer and Matched Norm Participants in the COVID-19 Crisis. <i>JAMA Oncology</i> , 2021, 7, 279.	7.1	56
24	RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 58.	1.6	55
25	Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: A nationwide populationâ€“based propensityâ€“score adjusted study in the Netherlands. <i>International Journal of Cancer</i> , 2016, 139, 2082-2094.	5.1	55
26	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, 4112.	12.8	55
27	Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. <i>European Journal of Cancer</i> , 2017, 76, 93-99.	2.8	54
28	Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. <i>Acta OncolÃ³gica</i> , 2013, 52, 950-955.	1.8	51
29	Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: A case-matched comparison with palliative systemic therapy. <i>Surgery</i> , 2017, 161, 909-919.	1.9	51
30	Management of liver metastases in colorectal cancer patients: A retrospective case-control study of systemic therapy versus liver resection. <i>European Journal of Cancer</i> , 2016, 59, 13-21.	2.8	50
31	Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 909-919.	7.3	42
32	Disease recurrence after colorectal cancer surgery in the modern era: a population-based study. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2399-2410.	2.2	42
33	The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 1580-1588.	1.5	38
34	Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: A retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). <i>Acta OncolÃ³gica</i> , 2012, 51, 831-839.	1.8	37
35	Doseâ€“Response and Doseâ€“Toxicity Relationships for Glass <sup>90</sup> Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1616-1623.	5.0	36
36	Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases. <i>JAMA Surgery</i> , 2021, 156, 710-720.	4.3	34

#	ARTICLE	IF	CITATIONS
37	MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2015, 6, 22996-23007.	1.8	34
38	Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment. <i>JAMA Surgery</i> , 2021, 156, 1093.	4.3	34
39	Developing a core set of patient-reported outcomes in pancreatic cancer: A Delphi survey. <i>European Journal of Cancer</i> , 2016, 57, 68-77.	2.8	33
40	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	2.8	29
41	Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).. <i>Journal of Clinical Oncology</i> , 2013, 31, 3502-3502.	1.6	29
42	EMAST Is Associated with a Poor Prognosis in Microsatellite Instable Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0124538.	2.5	28
43	Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data. <i>International Journal of Cancer</i> , 2021, 148, 296-306.	5.1	27
44	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2052-2060.	1.6	26
45	Reversible Posterior Leukoencephalopathy Syndrome Caused by Bevacizumab: Report of a Case. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 1425-1426.	1.3	23
46	Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial. <i>Cancer Medicine</i> , 2020, 9, 1033-1043.	2.8	23
47	Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models. <i>BMC Medical Research Methodology</i> , 2017, 17, 170.	3.1	19
48	Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era. <i>British Journal of Cancer</i> , 2021, 124, 399-406.	6.4	19
49	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 63140-63154.	1.8	19
50	Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. <i>Cancer Epidemiology</i> , 2018, 57, 60-67.	1.9	18
51	Health-related quality of life in rectal cancer patients undergoing neoadjuvant chemoradiation with delayed surgery versus short-course radiotherapy with immediate surgery: a propensity score-matched cohort study. <i>Acta Oncologica</i> , 2019, 58, 407-416.	1.8	18
52	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	6.3	17
53	Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA388-LBA388.	1.6	16
54	Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review. <i>Cancers</i> , 2022, 14, 2218.	3.7	16

#	ARTICLE	IF	CITATIONS
55	Chemotherapy, which drugs and when. <i>European Journal of Cancer</i> , 2009, 45, 50-56.	2.8	15
56	Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 1395-1403.	4.7	15
57	The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 919-928.	7.3	15
58	A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research. <i>Cancer Treatment Reviews</i> , 2021, 95, 102174.	7.7	15
59	Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3504-3504.	1.6	15
60	Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm. <i>European Journal of Cancer</i> , 2017, 81, 130-134.	2.8	14
61	Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer. <i>Clinical Pharmacokinetics</i> , 2018, 57, 455-473.	3.5	14
62	<sup>19</sup> F MRSI of capecitabine in the liver at 7T using broadband transmit-receive antennas and dual-band RF pulses. <i>NMR in Biomedicine</i> , 2015, 28, 1433-1442.	2.8	13
63	The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care. <i>Scientific Reports</i> , 2021, 11, 3923.	3.3	13
64	Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review. <i>European Journal of Cancer</i> , 2016, 69, 166-177.	2.8	12
65	Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review. <i>European Journal of Cancer</i> , 2017, 86, 166-177.	2.8	12
66	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	6.3	12
67	Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2014, 759, 37-44.	1.0	11
68	Reduced rate of copy number aberrations in mucinous colorectal carcinoma. <i>Oncotarget</i> , 2015, 6, 25715-25725.	1.8	11
69	Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. <i>British Journal of Cancer</i> , 2017, 117, 1768-1776.	6.4	10
70	Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz014.	2.9	10
71	Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer. <i>Medical Decision Making</i> , 2019, 39, 57-73.	2.4	10
72	Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer. <i>Cells</i> , 2020, 9, 2688.	4.1	10

#	ARTICLE	IF	CITATIONS
73	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. <i>Pharmacoeconomics</i> , 2020, 38, 683-713.	3.3	10
74	WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4612-4622.	7.0	9
75	Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer. <i>Patient Education and Counseling</i> , 2019, 102, 1331-1335.	2.2	9
76	The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 737-744.	1.9	8
77	Monitoring potentially modifiable lifestyle factors in cancer survivors: A narrative review on currently available methodologies and innovations for large-scale surveillance. <i>European Journal of Cancer</i> , 2018, 103, 327-340.	2.8	8
78	Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world data. <i>International Journal of Cancer</i> , 2020, 146, 2968-2978.	5.1	8
79	European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment. <i>European Journal of Cancer</i> , 2020, 138, 99-108.	2.8	8
80	Interaction Between Primary Tumor Resection, Primary Tumor Location, and Survival in Synchronous Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 315-324.	1.3	8
81	Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102226.	7.7	8
82	The era of alternative designs to connect randomized clinical trials and real-world data. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 589-589.	27.6	7
83	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 394.	2.6	7
84	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	5.9	6
85	Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. <i>Acta Oncologica</i> , 2020, 59, 395-403.	1.8	6
86	Recent changes in overall survival of real-life stage IV colorectal cancer patients. <i>Journal of Clinical Oncology</i> , 2019, 37, 3522-3522.	1.6	6
87	Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). <i>Clinical Colorectal Cancer</i> , 2022, 21, 154-166.	2.3	6
88	Angiogenesis in 90Y-Radioembolization of Colorectal Liver Metastases. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 204-210.	4.6	5
89	Modeling Personalized Adjuvant Treatment in Early stage colon cancer (PATTERN). <i>European Journal of Health Economics</i> , 2020, 21, 1059-1073.	2.8	5
90	Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework. <i>Clinical Cancer Research</i> , 2020, 26, 4892-4900.	7.0	5

#	ARTICLE	IF	CITATIONS
91	Mismatch Repair Status in Patient-Derived Colorectal Cancer Organoids Does Not Affect Intrinsic Tumor Cell Sensitivity to Systemic Therapy. <i>Cancers</i> , 2021, 13, 5434.	3.7	5
92	Translation of <scp>IDEA</scp> trial results into clinical practice: Analysis of the implementation of a new guideline for colon cancer. <i>International Journal of Cancer</i> , 2022, 151, 1270-1279.	5.1	5
93	Maintenance treatment in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, e582-e583.	10.7	4
94	Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group. <i>Clinical Colorectal Cancer</i> , 2019, 18, e229-e230.	2.3	4
95	Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 240.	2.4	4
96	Practice Variation in the Adjuvant Treatment of Colon Cancer in the Netherlands: A Population-based Study. <i>Anticancer Research</i> , 2020, 40, 4331-4341.	1.1	4
97	Clinical outcomes of biliary drainage of malignant biliary obstruction due to colorectal cancer metastases: A systematic review. <i>European Journal of Internal Medicine</i> , 2021, 88, 81-88.	2.2	4
98	Impact of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) on time to progression and overall survival (OS) in metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10087-10087.	1.6	4
99	Systemic Treatment: Maintenance Compared with Holiday. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 85-90.	3.8	3
100	Cost-effectiveness in colorectal cancer: challenges on quality and comparability. <i>Colorectal Cancer</i> , 2016, 5, 21-31.	0.8	3
101	Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer. <i>Acta OncolÃ³gica</i> , 2019, 58, 326-333.	1.8	3
102	Model-based evaluation of the cost effectiveness of 3 <i>i&gt;</i> versus</i>6 monthsâ€™ adjuvant chemotherapy in high-risk stage II colon cancer patients. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482095411.	3.2	3
103	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	3.2	3
104	Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study. <i>International Journal of Cancer</i> , 2021, 148, 2702-2711.	5.1	3
105	Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199571.	3.2	3
106	Colorectal Cancer Care and Patientâ€™s Perceptions Before and During COVID-19: Implications for Subsequent SARS-CoV-2 Infection Waves. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab047.	2.9	3
107	Mode of progression after radioembolization in patients with colorectal cancer liver metastases. <i>EJNMMI Research</i> , 2020, 10, 107.	2.5	3
108	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	3

#	ARTICLE	IF	CITATIONS
109	External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort. <i>Cancers</i> , 2022, 14, 2356.	3.7	3
110	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. <i>European Journal of Cancer</i> , 2018, 96, 115-124.	2.8	2
111	Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124766.	5.9	2
112	Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer. <i>Value in Health</i> , 2021, 25, 104-115.	0.3	2
113	Receipt and survival outcomes by age following second-line therapy for metastatic CRC (mCRC): Analysis of 5,289 patients from the ARCAD Clinical Trials Program.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6-6.	1.6	2
114	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	6.3	2
115	Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective. <i>Future Oncology</i> , 2022, 18, 1313-1320.	2.4	2
116	Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 1001.	3.7	2
117	Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. <i>Indian Journal of Surgical Oncology</i> , 2012, 3, 57-65.	0.7	1
118	Duration of adjuvant treatment for patients with stage III colon cancer. <i>Lancet Oncology</i> , The, 2020, 21, 1545-1547.	10.7	1
119	Role of Up-Front Primary Tumor Resection and Tumor Sidedness in the Survival of Synchronous Metastatic Colon Cancer Patients. <i>Digestive Surgery</i> , 2021, 38, 283-289.	1.2	1
120	Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3640-3640.	1.6	1
121	The Prospective Dutch Colorectal Cancer (PLCRC) Cohort: Towards a unique patient-reported outcome enriched "real-world" data cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 52-52.	1.6	1
122	RE: Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv104-djv104.	6.3	0
123	Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1726-1734.	2.5	0
124	Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3552-3552.	1.6	0
125	The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer" A randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3630-TPS3630.	1.6	0
126	The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer" A randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS782-TPS782.	1.6	0



#	ARTICLE	IF	CITATIONS
127	Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database.. Journal of Clinical Oncology, 2016, 34, 658-658.	1.6	0
128	An individual patient data (IPD) meta-analysis of the impact of thrombocytosis (↑plts) on overall survival (OS) whilst using an intermittent chemotherapy (iCTx) strategy in advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 2017, 35, e15044-e15044.	1.6	0
129	Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in the Netherlands: A population-based study.. Journal of Clinical Oncology, 2019, 37, 6612-6612.	1.6	0
130	Clinical implications of assumptions in cost-effectiveness analyses of systemic therapies for metastatic colorectal cancer.. Journal of Clinical Oncology, 2020, 38, e16021-e16021.	1.6	0
131	Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program.. Journal of Clinical Oncology, 2020, 38, 7009-7009.	1.6	0
132	Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival based on real-life data.. Journal of Clinical Oncology, 2020, 38, 32-32.	1.6	0
133	Baseline treatment patterns of the first 277 patients in PROMETCO: A real-world, prospective, longitudinal cohort study on the continuum of care in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, 55-55.	1.6	0
134	External validation of the MSKCC nomogram to estimate five-year overall survival after surgery for stage III colon cancer in a Dutch population. Acta Oncologica, 2022, 61, 560-565.	1.8	0
135	Evaluation of an individual feedback report on patient-reported outcomes in the Prospective Dutch ColoRectal Cancer cohort. Supportive Care in Cancer, 0, , .	2.2	0
136	Clinical Outcomes of Biliary Drainage in Patients with Malignant Biliary Obstruction Caused by Colorectal Cancer Metastases. Journal of Gastrointestinal Cancer, 0, , .	1.3	0